Why Solbar Ningbo Protein Technology's (SHSE:603231) Shaky Earnings Are Just The Beginning Of Its Problems
Why Solbar Ningbo Protein Technology's (SHSE:603231) Shaky Earnings Are Just The Beginning Of Its Problems
Solbar Ningbo Protein Technology Co., Ltd.'s (SHSE:603231) recent weak earnings report didn't cause a big stock movement. We think that investors are worried about some weaknesses underlying the earnings.
宁波索尔巴蛋白科技股份有限公司(SHSE: 603231)最近的弱盈利报告并未引起股价大幅波动。我们认为投资者担心盈利的一些潜在弱点。
The Impact Of Unusual Items On Profit
除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。
To properly understand Solbar Ningbo Protein Technology's profit results, we need to consider the CN¥14m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. If Solbar Ningbo Protein Technology doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
要正确理解宁波索尔巴蛋白科技的盈利结果,我们需要考虑到1400万人民币的非常规项目收益。我们不能否认较高的利润通常会让我们感到乐观,但我们更希望利润能够持续。当我们分析全球绝大多数上市公司时,我们发现重要的非常规项目通常不会重复。这并不令人意外,考虑到名称。如果宁波索尔巴蛋白科技没有看到这种贡献再次出现,那么其他条件不变,我们预计其利润在今年将下降。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Solbar Ningbo Protein Technology.
注意:我们始终建议投资者检查资产负债表的强度。点击此处查看我们对宁波索尔巴蛋白科技公司资产负债表分析。
Our Take On Solbar Ningbo Protein Technology's Profit Performance
我们对宁波索尔巴蛋白科技公司的利润表现的看法
We'd posit that Solbar Ningbo Protein Technology's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Solbar Ningbo Protein Technology's statutory profits are better than its underlying earnings power. But at least holders can take some solace from the 16% per annum growth in EPS for the last three. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. Every company has risks, and we've spotted 1 warning sign for Solbar Ningbo Protein Technology you should know about.
我们认为,Solbar宁波蛋白科技的法定收益并不能完全反映其持续生产力,这是由于大额非常项目所致。因此,我们认为Solbar宁波蛋白科技的法定利润可能优于其基本盈利能力。但至少股东可以从过去三年每股收益16%的年均增长获得一些慰藉。归根结底,若要正确理解该公司,必须考虑更多因素。考虑到这一点,如果您想对该公司进行更多分析,就必须了解涉及的风险。每个公司都有风险,我们在Solbar宁波蛋白科技中发现了1个警示信号,您应该了解一下。
Today we've zoomed in on a single data point to better understand the nature of Solbar Ningbo Protein Technology's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
今天我们聚焦于一项单一数据以更好地了解Solbar宁波蛋白科技的利润性质。但是,如果您能集中注意力于细枝末节,总能发现更多。有些人认为高净资产收益率是优质企业的好迹象。因此,您可能希望查看这个拥有高净资产收益率的公司收藏,或者这个拥有高内部股权的股票列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。